ANIX (Anixa Biosciences) Short Percentage of Float


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $2.64
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

ANIX vs PYPD, LONA, SGMO: Short Percentage of Float Comparison

For the Biotechnology subindustry, Anixa Biosciences's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Anixa Biosciences Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Short Percentage of Float falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.64
Price